MétaCan
ENFR
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

Export CSVExport JSONAPI query

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
American Heart Journal
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

1,105 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
1,105 works in the cohort · of 4,299,418page 5 of 23

Labels cover 0 of 1,105 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 1,105 of 1,105 works in this cohort. Predictions are machine_predicted_unvalidated teacher distillation outputs. Candidate is the union; consensus is the intersection.

affunlabeled
An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial
Renato D. Lópes, Amit N. Vora, Danny Liaw, Christopher B. Granger, Harald Darius, Shaun G. Goodman +3 more
2018· article· en· American Heart Journal· Medicine
distilled prediction:candidate · noneconsensus · none
87
citations
afffundno abstractunlabeled
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study
Thomas J. Povsic, Candice Junge, Adel Nada, Richard A. Schatz, Robert A. Harrington, Charles J. Davidson +10 more
2013· article· en· American Heart Journal· Medicine
distilled prediction:candidate · noneconsensus · none
87
citations
affunlabeled
Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction
C. Michael Gibson, John J.P. Kastelein, Adam Phillips, Philip E. Aylward, Megan K. Yee, Michał Tendera +15 more
2020· article· en· American Heart Journal· Medicine
distilled prediction:candidate · noneconsensus · none
85
citations
affno abstractunlabeled
Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): The first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction
Monica Taljaard, Michael R. Ward, Michael J.B. Kutryk, David W. Courtman, Nancy Camack, Shaun G. Goodman +4 more
2010· article· en· American Heart Journal· Biochemistry, Genetics and Molecular Biology
distilled prediction:candidate · noneconsensus · none
84
citations
affno abstractunlabeled
Correlation between the TIMI risk score and high-risk angiographic findings in non–ST-elevation acute coronary syndromes: Observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial
Jessica L. Mega, David A. Morrow, Marc S. Sabatine, Xue-Qiao Zhao, Steven Snapinn, Peter M. DiBattiste +4 more
2005· article· en· American Heart Journal· Medicine
distilled prediction:candidate · noneconsensus · none
81
citations
affno abstractunlabeled
Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI)
Sergio Leonardi, Sunil V. Rao, Robert A. Harrington, Deepak L. Bhatt, C. Michael Gibson, Matthew T. Roe +9 more
2010· article· en· American Heart Journal· Medicine
distilled prediction:candidate · noneconsensus · none
79
citations
affno abstractunlabeled
Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial
Kevin R. Bainey, Sherali A. Rahim, Krystal Etherington, Michael L. Rokoss, Madhu K. Natarajan, James L. Velianou +2 more
2015· article· en· American Heart Journal· Medicine
distilled prediction:candidate · metaepi_narrowconsensus · none
75
citations
← previousnext →

How this was built: Screen · Findings · About